Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Subscribe To Our Newsletter & Stay Updated
